A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Trial Profile

A Randomized, 30-week, Active-controlled, Open Label, 2- Treatment Arm, Parallel-group, Multicenter Study Comparing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination to Insulin Glargine With or Without Metformin in Patients With Type 2 Diabetes Mellitus (T2DM)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Insulin-glargine/lixisenatide (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LixiLan-L
  • Sponsors Sanofi
  • Most Recent Events

    • 26 Jun 2018 Post hoc analysis results from LixiLan-O and LixiLan-L studies were presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results of a post-hoc analysis assessing the effect of a fixed-ratio combination of insulin glargine U100 and the GLP-1 RA lixisenatide, on the proportion of patients with T2D with discordant HbA1c/FPG presented at the 78th Annual Scientific Sessions of the American Diabetes Association
    • 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top